Dr. Sands is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6049
Education & Training
University of California Davis HealthFellowship, Hematology and Medical Oncology, 2009 - 2012- University of California Davis HealthResidency, Internal Medicine, 2005 - 2008
University of Cincinnati College of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2023 - Present
RI State Medical License 2023 - 2026
VT State Medical License 2023 - 2026
CT State Medical License 2023 - 2025
MA State Medical License 2012 - 2025
ME State Medical License 2023 - 2025
NH State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
- Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients Start of enrollment: 2017 Oct 24
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2018 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 216 citationsLurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJose Manuel Trigo, Vivek Subbiah, Benjamin Besse, Victor Moreno, Rafael López
The Lancet. Oncology. 2020-05-01 - 173 citationsSmall Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Apar Kishor P Ganti, Billy W Loo, Michael Bassetti, Collin Blakely, Anne Chiang
Journal of the National Comprehensive Cancer Network. 2021-12-01 - 188 citationsTumor innate immunity primed by specific interferon-stimulated endogenous retrovirusesIsrael Cañadas, Rohit Thummalapalli, Jong Wook Kim, Shunsuke Kitajima, Russell W. Jenkins
Nature Medicine. 2018-08-01
Journal Articles
- Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous RetrovirusesScott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature
Press Mentions
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III TrialSeptember 9th, 2024- Unlocking ASCO 2024: Must-Know BreakthroughsJuly 11th, 2024
- Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung CancerMay 17th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
